JunCell Biosciences Launches China's First Registered TIL Therapy Clinical Trial for Lung Cancer with GC101
Juncell Therapeutics
Solid Tumor Cell Therapy Developer
October 14, 2024Juncell Therapeutics Sponsored "An Open-Label, Single-Arm, Phase Ib Clinical Trial Evaluating the Safety and Efficacy of Autologous Natural Tumor-Infiltrating Lymphocyte Injection (GC101 TIL) in Patients with Advanced Non-Small Cell Lung Cancer (MIZAR-005)"Kick-off Meeting, held in both online and offline formats at the group leader unitShanghai Chest HospitalSuccessfully convened.Prof. Lu Shun and Director Li Ziming from the Department of Oncology, Shanghai Chest Hospital, and Director Chu Tianqing from the Drug Clinical Trial InstitutionAnd related clinical research teams, Juncell Therapeutics Vice President Lin Shuwei and the clinical medicine team attended the project kick-off meeting.
This isChina's First TIL Cell Drug Registration Clinical Trial Specifically for Lung Cancer, which also marks Juncell Therapeutics inExpansion of TIL Therapy for Solid Tumor IndicationsAnother important progress.
"Targeted therapies and immunotherapies for advanced non-small cell lung cancer have made significant progress in recent years, but challenges such as overcoming drug resistance mechanisms and addressing tumor heterogeneity still remain. As a research hotspot in the field of solid tumor cell therapy, we are pleased to collaborate with Juncell Therapeutics to apply this highly promising innovative therapy in clinical research for non-small cell lung cancer. We look forward to sharing the future clinical research progress of GC101 with everyone, hoping that this innovative TIL therapy will benefit more lung cancer patients."
"For patients with non-small cell lung cancer, there are still clinical needs forHigher SafetyAndUnmet Needs in Cell Therapy for Longer-Lasting Efficacy.GC101The early clinical trial data showed promising efficacy. In this project, we look forward to further discovering and understanding the potential and possible advantages of this TIL therapy in treating non-small cell lung cancer patients, providing innovative treatment options for patients.”
"Based on the extensive project learning in the early stages, we are highly anticipating this clinical study. We hope that through our joint efforts,Boldly and Carefully Complete Clinical Trials, Prove the Safety and Effectiveness of This TIL Therapy in Lung Cancer, Offer More Hope for Lung Cancer Patients!”
About GC101
GC101Relying on Juncell Therapeutics' independently developed, world-leading DeepTIL®Developed from a cell enrichment and expansion platform,It is the TIL therapy pipeline with the fastest R&D progress by Juncell Therapeutics, and alsoThe World's First Natural TIL Therapy That Requires No Lymphodepletion and No IL-2 Injection, while enhancing the efficacy of TIL, significantly improve the safety and accessibility of TIL therapy, and reduce the numerous restrictions on patients' physical conditions.
Clinical data show that GC101 has achieved an objective response rate (ORR) of over 35% in treating various types of advanced solid tumors, with four patients having their tumors completely eliminated, reaching complete response (CR). The longest tumor-free survival time has reached 3 years.
AboutMIZAR-005Clinical Trial
MIZAR-005 isAn Open-Label, Single-Arm, Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Autologous Natural Tumor-Infiltrating Lymphocyte Injection (GC101 TIL) in Patients with Advanced Non-Small Cell Lung Cancer。
6. Have adequate hematologic and end-organ function.
4. Brain metastasis with clinical symptoms or unstable lesion size.
Teacher Cheng: 18001759113 (Same as WeChat)
About Juncell Therapeutics
Juncell Therapeutics will steadfastly uphold the noble mission of "Refining Cells, Safeguarding Life," embrace the inspiring vision of "Creating Miracles with Science, Making Miracles Commonplace," and adhere to the core values of "Focus, Innovation, Inclusiveness, and Sharing." The company is committed to developing more high-quality TIL innovative therapies to meet the diverse needs of cancer patients.
E.N.D
Previous article recommendations:
Hengrui Medicine Subsidiary’s AAV Dual-Gene Drug Approved for Clinical Trials in China
Ru Jian Pharmaceuticals Completes Over 100 Million Yuan in Series B Financing
Akeso Successfully Raises HKD 1.942 Billion in Financing
Former mRNA Vaccine Star Company Enters Bankruptcy Proceedings
Clinical Results of In Vivo CAR-T Therapy Published for the First Time
For DMD, the Market Application of This Exosome Cell Therapy is About to be Completed
Global Leading Major Breakthrough! 20 Children with Refractory Lupus Erythematosus Successfully Discontinued All Hormones and Immunosuppressants After Receiving CAR-T Therapy at Children's Hospital of Zhejiang University
mRNA-LNP In Vivo Gene Editing Therapy Advances to Phase 3 Clinical Trials
Northland Shanghai Branch Opens, Fully Layouts the Commercialization of Gene Therapy Drug NL003
New Drug for ALS Approved! Biogen's "Tofersen Injection" Launched in China
WuXi AppTec Responds to Rumors of Selling Cell and Gene Therapy Business, Citing Uncertainty
2024 Nobel Prize in Physiology or Medicine Announced!
Juncell Therapeutics' iPS Cell-Derived Cell Therapy IND Accepted for Review
Covering an Area of Over 30,000 Square Feet, Juncell Therapeutics Builds New Cell Therapy R&D Base
Ten Key Areas in China's Biopharmaceutical Industry Worth Watching in the Next Decade
The Competitive Landscape of Gene Editing Therapy in China
Gene Editing Therapy Breakthroughs in China, Set to Enter a Period of Rapid Development
A Cell Therapy Specialty Hospital in Beidaihe Officially Begins Operation
AAV Gene Therapy Improves Patients' Vision Over a Hundredfold